Novel two-chain structure utilizing KIRS2/DAP12 domain improves the safety and efficacy of CAR-T cells in adults with r/r B-ALL

Novel two-chain structure utilizing KIRS2/DAP12 domain improves the safety and efficacy of CAR-T cells in adults with r/r B-ALL

Engineered T cells that express chimeric antigen receptors (CARs) have been a promising therapy for hematologic malignancies. The optimization of CAR structure using different signaling domains can alter a wide range of CAR-T cell properties, including anti-tumor activity, long-term persistence, and...

Full description

Bibliographic Details
Main Authors: Ming Sun, Peipei Xu, Enxiu Wang, Min Zhou, Tongpeng Xu, Jing Wang, Qian Wang, Bo Wang, Kaihua Lu, Chen Wang, Bing Chen
Format: Article
Language:English
Published: Elsevier 2021-12-01
Series:Molecular Therapy: Oncolytics
Subjects:
r/r B-ALL
CAR-T cells
KIRS2/DAP12 signaling domain
4-1BB
clinical trial
Online Access:http://www.sciencedirect.com/science/article/pii/S237277052100125X

Internet

http://www.sciencedirect.com/science/article/pii/S237277052100125X

Similar Items